Group 3 Fabiha Aziz Fariha Munir Fatima Tuz

Group 3 Fabiha Aziz Fariha Munir Fatima Tuz

Group 3 Fabiha Aziz Fariha Munir Fatima Tuz Zahra Fatima Tuz Zahra Kh Muhammad Ahmad Saneea Imran

Tatheer Fatima Contents 1.Introduction of the disease or disorder 2.Types of mutations involved 3.Conventional treatment 4.Type of vector 5.The procedure of gene therapy

6.History of clinical trials 7.Commercially available treatments Introduction What is hemophilia? What is does to our body? What causes hemophilia?

What is hemophilia? Hemophilia is an inherited bleeding disorder in which the blood fails to clot effectively. Hemophiliacs do not bleed more extensively or more quickly than the normal people but they do bleed for a longer time after an injury or surgery. What it does to our body?

The bleeding may be internal or external Internal bleeding occurs in knees ankles tissues and muscles. If left untreated the bleeding in the joints may lead to agonizing pain And can be fatal when the bleeding occurs in the vital organ like brain Hemophilia A

All races Affects men and women become carriers as gene is present on the X chromosome. Factor Replacement Therapy MUTATION By: Fatima Tuz Zahra

Mutation of Hemophilia A Coagulation factors are proteins that work together in the blood clotting process. F8 gene provides instructions for making a coagulation factor VIII Mutations in the F8 gene lead to the production of an abnormal version of coagulation factor VIII.

28 region of X Chromosome. Inversion and Crossing Over of Intron22 Conventional Treatments

By: Tatheer Fatima Conventional treatment The two main approaches to treatment are Preventive treatment : Refers to the regular medications that are taken to prevent episodes of bleeding and subsequent complications

Episodic treatment : Used to manage episodes of prolonged bleeding. Conventional treatment Treatment With Replacement Therapy : Concentrates of clotting factor VIII (hemophilia A) or clotting factor IX (hemophilia B) are slowly dripped or injected into a vein

Preparation of clotting factor concentrate : Human Blood Clotting factor concentrate Recombinant Clotting factors Conventional treatment Types of Replacement therapy : Preventive or prophylactic therapy: Replacement therapy on a regular basis to prevent

bleeding Demand therapy: only need replacement therapy to stop bleeding when it occurs Conventional treatment 1.

2. 3. 4. PROS Quicker treatment. Early treatment lowers the risk of

complications Fewer visits to the doctor or emergency room Costs less than treatment in a medical care setting Helps children accept

treatment and take responsibility for their own health CONS 1. Antibody(proteins) that attack the clotting factor

2. Viral infections from human clotting factors 3. Damage to joints, muscles, or other parts of the body resulting from delays

Conventional treatment Desmopressin Man made hormone Can treat mild hemophilia A Cannot treat hemophilia B or severe hemophilia A Stimulates the release of stored factor VIII Injection or as nasal spray Only in certain situations. e.g. you may take this

medicine prior to dental work or before playing certain sports to prevent or reduce bleeding Conventional treatment Anti fibrinolytic Medicines Tranexamic acid and epsilon aminocaproic acid Can be used with replacement therapy Given as a pill and they help keep blood clots from

breaking down. Most often are used before dental work or to treat bleeding from the mouth or nose or mild intestinal bleeding. Types of vector By: Muhammad Ahmed

Ex-vivo Cells transduced in culture, then returned to patient Greater control over transfection conditions Unchanged cells can be screened out Difficult to transpant In-vivo Cells modified within the body

Introduction of vector with genetic material in patients body No transplantation issues Cost-effective May provoke immune system Ultimate goal for gene therapy Viral Vectors

Retroviral vectors Moloney murine leukemia virus (MoMLV)-based Can infect wide variety, integrate into host genome, relatively non-immunogenic Only in actively dividing cells Problems: insertional mutagenesis, inactivation by complement

Adenoviral vectors Relatively large, double-stranded DNA viruses Infect non-dividing cells Can transfer multiple copies of gene, in vivo Problems: Many humans may be immune to virus, not integrated into host genome

Adeno-associated (AAV) vectors Relatively small, single stranded DNA parvovirus Viral coding sequence replaced by transgene Non-dividing cells Lentiviral Vectors Integrate into genome, infect non-dividing cells Problems: limited range of cell targets, pathogens!

HIV big risk of recombination infectious virus Non-Viral Vectors Through plasmids Problem: Transient expression of genes (several days) Direct injection of naked DNA

Problems: Low efficiency of transduction, not integrated into genome Procedure of Gene Therapy for Hemophilia A By: Saneea Imran

Gene therapy for hemophilia A Hemophilia is an interesting target for gene therapy as the genetics of the disease are well understood. Introducing a functional copy of the mutated gene through a vector can provide an effective cure. Phenotype

Clotting factor level = Clinical Gene therapy for Hemophilia A Vector: Both viral and non-viral vectors can be used Target Cell: Hematopoietic stem cells, hepatocytes, skeletal muscle cells, endothelial cells.

Approach: Both in-vivo and ex-vivo gene therapy approach can be used. Non-Viral vector for gene therapy of Hemophilia A Year: 2001 Non-viral somatic cell gene therapy for hemophilia A Vector used: Plasmid

Cells targeted: Dermal fibroblasts Procedure Desired gene that produces Factor VIII Restriction enzymes

Preparing the vector Gene of interest Transfection

Antibioti c gene Dermal fibroblasts of patient ( skin biopsy ) Cells that

successfully produce FVIII are selected and inserted into patient

Patient with Hemophilia Viral Vectors for gene therapy of Hemophilia A Vectors that have been used are: 1. Retroviral and Lentiviral Vectors 2. Adeno Associated Viral Vectors

Using Retroviral Vectors Producing recombinant Retroviral vectors Targeting cells with Retrovirus Clinical Trials

By: Fatima Tuz Zahra Khan Stem cell-based gene transfer Implantation of Genetically Modified Stem Cells Genetic modification and transplantation of hemopoietic stem cells (HSCs) Use of Retroviral and lentiviral vectors Trials remain un-successful due to insufficient levels

of FVIII In Vivo methods Retroviral vectors Retroviral vectors transduce replicating cells by stably integrating into the host genome. Preclinical studies involving rabbits and dogs did show possible benefits.

Routes? Subjects received a peripheral intravenous infusion of retroviral vector carrying a B domaindeleted human FVIII gene. Efficiency? 9 of 12 subjects showed a FVIII level above 1% Insertional mutagenesis and the risk of subsequent

LENTIVIRAL VECTORS Lentiviruses efficiently transduce nondividing cells. Overcoming a hurdle faced by retroviral vector systems. Routes? In murine models, intraperitoneal administration of lentivirus transduced liver, spleen, blood and bone marrow Efficieny? four- to sixfold rise in expression

Concerns over genomic integration and subsequent malignancy. ADENOVIRAL VECTORS One of the most efficient vectors Transducing dividing and nondividing cells, with a tropism for hepatocytes Genetic payload capacity making them ideal vectors for

the FVIII gene Routes? Intramuscular Injection. Liver-directed administration Efficiency? Single Human Trail Adeno associated Virus:

Success in mouse and other large animal models. Limitations due to small genome size. Routes? Intramuscular Injection. Liver-directed administration Efficiency? Two trials have examined the use of AAV-2 vectors in human subjects

Limited efficacy Commercially available Treatments Treatment Regular infusions of DDAVP or clotting factor Clot-preserving medications (antifibrinolytics)

Fibrin sealants Physical therapy First aid for minor cuts Vaccinations Clinical Trials Currently are for hemophilia B AAV vector encoding factor IX (FIX) under the

control of a liver-restricted promoter Promising results Problems First clinical trial of hepatic artery infusion of an AAV2-FIX vector quickly encountered obstacles that had not been identified in the preclinical studies Risk of vertical transmission

Risk for potential offspring if the spermatocytes are transduced References Haemophilia A: from mutation analysis to new therapies Jochen Graw, Hans-Hermann Brackmann, Johannes Oldenburg, Reinhard Schneppenheim, Michael Spannagl & Rainer Schwaab Genetics Home Reference

(http://ghr.nlm.nih.gov/condition/hemophilia) http://www.visibleproductions.com/index.php?page=asset_detail&asset_id=vpl_ 0715_001

Recently Viewed Presentations

  • Carbaugh, Intl Economics, Chapter 2

    Carbaugh, Intl Economics, Chapter 2

    By Robert J. Carbaugh 9th Edition Chapter 2: Foundations of Modern Trade Theory Historical development of trade theory Mercantilism Regulation to ensure a positive trade balance Critics: possible only for short term; assumes static world economy Absolute advantage (Adam Smith)...
  • Loop and Nodal Analysis and Op Amps

    Loop and Nodal Analysis and Op Amps

    Times New Roman Arial Wingdings Comic Sans MS Symbol Professional 1_Professional Microsoft Equation 3.0 Circuits II EE221 Unit 9 Instructor: Kevin D. Donohue Mutual Inductance Mutual Inductance Dot Convention Dot Notation for KVL Equivalent Circuits Example Examples Examples
  • A Soliloquy Hamlet Prince of Denmark hamlet@gov.dk -I

    A Soliloquy Hamlet Prince of Denmark [email protected] -I

    A Soliloquy Hamlet Prince of Denmark [email protected] -- I welcome feedback! Overview Not sure about audience Using powerpoint Help structure my thoughts Produce an action plan!
  • HEAD/NECK IV: Cranial Nerves - Yavapai College

    HEAD/NECK IV: Cranial Nerves - Yavapai College

    Optic Cribiform plate (ethmoid) Olfactory epithelium I. Olfactory EXIT FROM CRANIAL CAVITY TARGET NERVE Human Anatomy, Frolich, Head/Neck IV: Cranial Nerves M&M, Table 14.3 Human Anatomy, Frolich, Head/Neck IV: Cranial Nerves EXIT CR. CAVITY TARGET NERVE Hypoglossal canal (occipital) Intrinsic,...
  • Chapter 1, Heizer/Render, 5th edition

    Chapter 1, Heizer/Render, 5th edition

    Future Worth Analysis. Must. compare alternatives for . equal . service (i.e. alternatives must . end. at the same time) Two ways to compare equal service: (The LCM procedure is used unless otherwise specified) (1) Least common . multiple (LCM)...
  • Culture and Gender - UTSA

    Culture and Gender - UTSA

    CULTURE, GENDER ROLES, and STEREOTYPES Culture and Gender Stereotypes Williams and Best (1982) studied 30 countries and found high pancultural agreement on the adjectives used to describe males and females. In all countries, adjectives associated with men were rated as...
  • Stronger. Together. One Microsoft

    Stronger. Together. One Microsoft

    Argentine consumers showed mixed results compared with the worldwide trend for consequences; they were less likely to say they had lost trust in others online vs. the prior year, but more likely to have lost trust in others offline
  • Một Số Hướng Dẫn Khi Soạn Câu Hỏi Trắc Nghiệm

    Một Số Hướng Dẫn Khi Soạn Câu Hỏi Trắc Nghiệm

    MỘT SỐ HƯỚNG DẪN KHI SOẠN CÂU HỎI TRẮC NGHIỆM * Một số hoạt động chính về Khảo thí năm học 2011 - 2012 Tổ chức làm đề và chấm thi thường xuyên cho các Bộ môn trong thi lý...